Presentation of Phase 1 Study for NKTR-102 by Lead Clinical Investigator, Dr. Daniel Von Hoff
Monday, June 02, 2008 6:30 PM CT
Welcome
Introduction - Howard W. Robin, President & CEO
Nektar Oncology Pipeline - Theresa Neuman, Ph.D.
Phase 1 Clinical Trial of NKTR-102 - Daniel D. Von Hoff, M.D., F.A.C.P.
Q and A Panel
Welcome
Introduction - Howard W. Robin, President & CEO
Nektar Oncology Pipeline - Theresa Neuman, Ph.D.
Phase 1 Clinical Trial of NKTR-102 - Daniel D. Von Hoff, M.D., F.A.C.P.
Q and A Panel